Jiuzhou Pharma (603456.SS)

Executive Summary

Jiuzhou Pharma is a publicly traded Contract Development and Manufacturing Organization (CDMO) based in China, with a strong focus on small molecule and peptide active pharmaceutical ingredients (APIs). Founded in 1998 and listed on the Shanghai Stock Exchange (ticker: 603456.SS), the company offers end-to-end services from preclinical development through commercial manufacturing. Jiuzhou differentiates itself through proprietary green manufacturing technologies, addressing the growing demand for environmentally sustainable pharmaceutical production. With over 1,000 employees and a market capitalization of approximately $13.2 billion, it serves a global client base, particularly in the generic and innovative drug sectors. As a CDMO, Jiuzhou Pharma benefits from the trend of pharmaceutical outsourcing, especially for complex molecules like peptides. The company's strong balance sheet and established track record position it well to capture market share in the expanding Chinese and international CDMO markets.

Upcoming Catalysts (preview)

• Q2 2027Completion and FDA/EU approval of new peptide manufacturing facility75% success
• Q4 2026Signing of a multi-year supply contract with a top-20 global pharma company for a blockbuster peptide API60% success
• Q1 2027Inclusion of key APIs in China's volume-based procurement (VBP) list, driving significant sales volume50% success